Brand-name drug
Depakote price, strengths & recalls
Brand of valproate (generic)
Pharmacies pay $110.52 for 30 tablets of Depakote 250 mg (24 hr) extended-release tablet this week, and from $58.96 to $223.78 across its 6 priced strengths and forms. The generic, valproate, costs pharmacies from $1.60. It is in shortage (unavailable). It has 10 recalls on record, none ongoing. Its official label last changed on April 14, 2026.
UnavailableBrand- Fair cash price
- $137.60
- Strengths
- 6
- Makers
- 1
- Updated
- Nov 11
Depakote price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 125 mg delayed-release capsule Brand | $1.97 | $58.96 / 30 capsules |
| 125 mg delayed-release tablet Brand | $2.06 | $61.78 / 30 tablets |
| 250 mg delayed-release tablet Brand | $4.04 | $121.26 / 30 tablets |
| 500 mg delayed-release tablet Brand | $7.46 | $223.78 / 30 tablets |
| 250 mg (24 hr) extended-release tablet Brand | $3.68 | $110.52 / 30 tablets |
| 500 mg (24 hr) extended-release tablet Brand | $6.49 | $194.76 / 30 tablets |
The lowest cost per capsule is 125 mg delayed-release capsule at $1.97. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Depakote vs generic valproate
Generics have the same active ingredient, strength and form, and FDA requires them to work the same way. What pharmacies pay for each, same quantity:
| Strength | Brand | Generic | Brand costs |
|---|---|---|---|
| 125 mg delayed-release capsule | $58.96 | $5.91 | 10x |
| 125 mg delayed-release tablet | $61.78 | $1.60 | 38.7x |
| 250 mg delayed-release tablet | $121.26 | $2.54 | 47.7x |
| 500 mg delayed-release tablet | $223.78 | $4.68 | 47.8x |
| 250 mg (24 hr) extended-release tablet | $110.52 | $4.16 | 26.6x |
| 500 mg (24 hr) extended-release tablet | $194.76 | $5.87 | 33.2x |
Supply status: shortages & recalls
Shortages
- Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05)Next release November 2026. Check wholesalers for inventory.
- Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)Additional lots will be available. Product will be made available as it is released.
In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.
Recalls
Showing the 6 most relevant of 10 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Depakote
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use Depakote safely and effectively. See full prescribing information for Depakote.Depakote (divalproex sodium) delayed-release tablets, for oral useInitial U.S. Approval: 1983
WARNING: LIFE THREATENING ADVERSE REACTIONS
Hepatotoxicity
General Population: Hepatic failure resulting in fatalities has occurred in patients receiving valproate and its derivatives. These incidents usually have occurred during the first six months of treatment. Serious or fatal hepatotoxicity may be preceded by non-specific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, and vomiting. In patients with epilepsy, a loss of seizure control may also occur. Patients should be monitored closely for appearance of these symptoms. Serum liver tests should be performed prior to therapy and at frequent intervals thereafter, especially during the first six months [see Warnings and Precautions (5.1)].
Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. When Depakote is used in this patient group, it should be used with extreme caution and as a sole agent. The benefits of therapy should be weighed against the risks. The incidence of fatal hepatotoxicity decreases considerably in progressively older patient groups.
Patients with Mitochondrial Disease: There is an increased risk of valproate-induced acute liver failure and resultant deaths in patients with hereditary neurometabolic syndromes caused by DNA mutations of the mitochondrial DNA Polymerase γ (POLG) gene (e.g., Alpers Huttenlocher Syndrome). Depakote is contraindicated in patients known to have mitochondrial disorders caused by POLG mutations and children under two years of age who are clinically suspected of having a mitochondrial disorder [see Contraindications (4)]. In patients over two years of age who are clinically suspected of having a hereditary mitochondrial disease, Depakote should only be used after other anticonvulsants have failed. This older group of patients should be closely monitored during treatment with Depakote for the development of acute liver injury with regular clinical assessments and serum liver testing. POLG mutation screening should be performed in accordance with current clinical practice [see Warnings and Precautions (5.1)].
Fetal Risk
Valproate can cause major congenital malformations, particularly neural tube defects (e.g., spina bifida). In addition, valproate can cause decreased IQ scores and neurodevelopmental disorders following in utero exposure.
Valproate is therefore contraindicated for prophylaxis of migraine headaches in pregnant women and in women of childbearing potential who are not using effective contraception [see Contraindications (4)]. Valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable.
Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. In such situations, effective contraception should be used [see Warnings and Precautions (5.2, 5.3, 5.4)].
A Medication Guide describing the risks of valproate is available for patients [see Patient Counseling Information (17)].
Pancreatitis
Cases of life-threatening pancreatitis have been reported in both children and adults receiving valproate. Some of the cases have been described as hemorrhagic with a rapid progression from initial symptoms to death. Cases have been reported shortly after initial use as well as after several years of use. Patients and guardians should be warned that abdominal pain, nausea, vomiting, and/or anorexia can be symptoms of pancreatitis that require prompt medical evaluation. If pancreatitis is diagnosed, valproate should ordinarily be discontinued. Alternative treatment for the underlying medical condition should be initiated as clinically indicated [see Warnings and Precautions (5.5)].
WARNING: LIFE THREATENING ADVERSE REACTIONS
See full prescribing information for complete boxed warning.
Hepatotoxicity, including fatalities, usually during the first 6 months of treatment. Children under the age of two years and patients with mitochondrial disorders are at higher risk. Monitor patients closely, and perform serum liver testing prior to therapy and at frequent intervals thereafter (5.1)
Fetal Risk, particularly neural tube defects, other major malformations, and decreased IQ (5.2, 5.3, 5.4)
Pancreatitis, including fatal hemorrhagic cases (5.5)
Recent major changes (as listed on the label)
Contraindications (4) | 5/2025 |
Warnings and Precautions (5.2, 5.3) | 3/2026 |
Warnings and Precautions (5.13, 5.14) | 5/2025 |
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA018723 · Abbvie
- First approved
- March 10, 1983 (43 years ago)
- Latest approved change
- March 31, 2026
- Approved label
- PDF, Apr 2, 2026
- Generic makers
- 29 approved generic applications on the market
Depakote questions
How much does depakote cost without insurance?
Pharmacies pay about $110.52 for 30 tablets of depakote 250 mg (24 hr) extended-release tablet ($3.68 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $137.60. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Depakote?
Yes: valproate. Pharmacies pay from $1.60 for it. Compare valproate prices.
Is depakote in shortage?
Yes. 2 products are listed as in shortage or being discontinued (unavailable). See which ones.
Has depakote been recalled?
10 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the depakote label last change?
The official label was last updated on April 14, 2026 (version 1621). See what changed.
Talk about depakote
No comments yet. Questions, tips, what worked for you - start the conversation.